The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | The value of BTK inhibitors in the treatment of frontline and relapsed MCL: expert insights
In this discussion, experts Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tycel Phillips, MD, City of Hope, Duarte, CA, and Craig Portell, MD, University of Virginia, Charlottesville, VA, discuss the value of BTK inhibitors in frontline and relapsed mantle cell lymphoma (MCL). They cover a variety of topics, including how to select between currently available agents, the toxicity profile of both covalent and non-covalent BTK inhibitors, managing side effects, and emerging trial data. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
